The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease
Open accessAbstract
On June 30, 2009, the United States Food and Drug Administration (FDA) approved ferumoxytol (Feraheme™ injection, AMAG Pharmaceuticals), an iron‐containing product for intravenous (IV) administration, for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD). The safety and efficacy of ferumoxytol were assessed in three randomized, open‐label, controlled clinical trials. Two trials evaluated patients with nondialysis dependent CKD and a third trial assessed patients undergoing hemodialysis. Randomization was either to ferumoxytol or oral iron. Ferumoxytol was administered as two 510 mg IV injections, separated by 3–8 days. Oral iron, Ferro‐Sequels®, was administered at a dose of 100 mg twice daily for 21 days. In all three clinical trials, ferumoxytol administration increased the mean blood hemoglobin (Hgb) concentrations by ∼1.0 g/dL over the 35 day period, a mean increase that was greater than what was observed in patients receiving oral iron. Patients receiving ferumoxytol also had increases in blood transferrin saturation (TSAT) and ferritin values. For the proposed ferumoxytol dosing regimen, 4.9% of patients had serum ferritin ≥800 ng/mL and TSAT ≥50% post‐treatment. The most important ferumoxytol safety concerns were hypersensitivity reactions and/or hypotension. Anaphylaxis or anaphylactoid reactions were reported in 0.2% of subjects, and other adverse reactions potentially associated with hypersensitivity (e.g., pruritus, rash, urticaria, or wheezing) were reported in 3.7%. Hypotension was observed in 1.9%, including three patients with serious hypotensive reactions. Ferumoxytol administration may transiently affect the diagnostic ability of magnetic resonance imaging and the drug label provides further information regarding this effect. Am. J. Hematol. 2010. Published 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Eckardt, K.-U., Tsukamoto, Y., Levin, A., Coresh, J., Rossert, J., Zeeuw, D. D. E., Hostetter, T. H., Lameire, N., & Eknoyan, G. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00365.x · Cited by 3,946
Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation
Wish, J. B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01490506 · Cited by 556
KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 Update
National Kidney Foundation (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.11.017 · Cited by 347
Shepshelovich, D., Rozen-Zvi, B., Avni, T., Gafter, U., & Gafter-Gvili, A. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.04.018 · Cited by 322
Iron and infection: the heart of the matter
Bullen, J. J., Rogers, H. J., Spalding, P. B., & Ward, C. G. (2005) · FEMS Immunology & Medical Microbiology · doi:10.1016/j.femsim.2004.11.010 · Cited by 273
Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease
Agarwal, R., Vasavada, N., Sachs, N. G., & Chase, S. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00648.x · Cited by 261
Strategies for iron supplementation: Oral versus intravenous
Macdougall, I. C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.055suppl.69061.x · Cited by 199
Ferumoxytol as an Intravenous Iron Replacement Therapy in Hemodialysis Patients
Provenzano, R., Schiller, B., Rao, M., Coyne, D., Brenner, L., & Pereira, B. J. G. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02840608 · Cited by 187
Silverberg, D. S., Iaina, A., Peer, G., Kaplan, E., Levi, B. A., Frank, N., Steinbruch, S., & Blum, M. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90546-6 · Cited by 173
Iron Status and Hemoglobin Level in Chronic Renal Insufficiency
Hsu, C.-Y., McCulloch, C. E., & Curhan, G. C. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034200.82278.dc · Cited by 172
Cited by
Ulbrich, K., Holá, K., Šubr, V., Bakandritsos, A., Tuček, J., & Zbořil, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00589 · Cited by 1,730
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
Imaging and drug delivery using theranostic nanoparticles
Janib, S. M., Moses, A. S., & MacKay, J. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.004 · Cited by 1,248
Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine
Donahue, N. D., Acar, H., & Wilhelm, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.008 · Cited by 944
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles
Arami, H., Khandhar, A., Liggitt, D., & Krishnan, K. M. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00541h · Cited by 830
Nanopharmaceuticals (part 1): products on the market
Weissig, V., Pettinger, T., & Murdock, N. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s46900 · Cited by 591
A framework for designing delivery systems
Poon, W., Kingston, B. R., Ouyang, B., Ngo, W., & Chan, W. C. W. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0759-5 · Cited by 524
García, K. P., Zarschler, K., Barbaro, L., Barreto, J. A., O'Malley, W., Spiccia, L., Stephan, H., & Graham, B. (2014) · Small · doi:10.1002/smll.201303540 · Cited by 519
Biologically Targeted Magnetic Hyperthermia: Potential and Limitations
Chang, D., Lim, M., Goos, J. A. C. M., Qiao, R., Ng, Y. Y., Mansfeld, F. M., Jackson, M., Davis, T. P., & Kavallaris, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00831 · Cited by 495
Tay, Z. W., Chandrasekharan, P., Chiu-Lam, A., Hensley, D. W., Dhavalikar, R., Zhou, X. Y., Yu, E. Y., Goodwill, P. W., Zheng, B., Rinaldi, C., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b00893 · Cited by 459
KDIGO clinical practice guidelines for bisphosphonate treatment in chronic kidney disease
Woo, K. T., & Chan, C. M. (2011) · Kidney International · doi:10.1038/ki.2011.202 · Cited by 412
Magnetic Particle Imaging: A Novel in Vivo Imaging Platform for Cancer Detection
Yu, E. Y., Bishop, M., Zheng, B., Ferguson, R. M., Khandhar, A. P., Kemp, S. J., Krishnan, K. M., Goodwill, P. W., & Conolly, S. M. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04865 · Cited by 366
Designing nanozymes for in vivo applications
Zhang, R., Jiang, B., Fan, K., Gao, L., & Yan, X. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00205-1 · Cited by 360
Synthesis of phase-pure and monodisperse iron oxide nanoparticles by thermal decomposition
Hufschmid, R., Arami, H., Ferguson, R. M., Gonzales, M., Teeman, E., Brush, L. N., Browning, N. D., & Krishnan, K. M. (2015) · Nanoscale · doi:10.1039/c5nr01651g · Cited by 341
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Magnetic Particle Imaging (MPI) for NMR and MRI researchers
Saritas, E. U., Goodwill, P. W., Croft, L. R., Konkle, J. J., Lu, K., Zheng, B., & Conolly, S. M. (2013) · Journal of Magnetic Resonance · doi:10.1016/j.jmr.2012.11.029 · Cited by 307
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Diagnosis and management of iron deficiency anemia in patients with IBD
Stein, J., Hartmann, F., & Dignass, A. U. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.151 · Cited by 304
X‐Space MPI: Magnetic Nanoparticles for Safe Medical Imaging
Goodwill, P. W., Saritas, E. U., Croft, L. R., Kim, T. N., Krishnan, K. M., Schaffer, D. V., & Conolly, S. M. (2012) · Advanced Materials · doi:10.1002/adma.201200221 · Cited by 301
MRI of Tumor-Associated Macrophages with Clinically Applicable Iron Oxide Nanoparticles
Daldrup-Link, H. E., Golovko, D., Ruffell, B., DeNardo, D. G., Castaneda, R., Ansari, C., Rao, J., Tikhomirov, G. A., Wendland, M. F., Corot, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3420 · Cited by 300
Disorders of iron metabolism. Part II: iron deficiency and iron overload
Muñoz, M., García-Erce, J. A., & Remacha, Á. F. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.086991 · Cited by 292
Evolution and clinical translation of drug delivery nanomaterials
Hassan, S., Prakash, G., Bal Ozturk, A., Saghazadeh, S., Farhan Sohail, M., Seo, J., Remzi Dokmeci, M., Zhang, Y. S., & Khademhosseini, A. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.008 · Cited by 288
Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications
Mohammadpour, R., Dobrovolskaia, M. A., Cheney, D. L., Greish, K. F., & Ghandehari, H. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.006 · Cited by 280
Jahn, M. R., Andreasen, H. B., Fütterer, S., Nawroth, T., Schünemann, V., Kolb, U., Hofmeister, W., Muñoz, M., Bock, K., Meldal, M., et al. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.03.016 · Cited by 256
Wu, C., Liu, Z., Chen, Z., Xu, D., Chen, L., Lin, H., & Shi, J. (2021) · Science Advances · doi:10.1126/sciadv.abj8833 · Cited by 255
Magnetic particle imaging with tailored iron oxide nanoparticle tracers
Ferguson, R. M., Khandhar, A. P., Kemp, S. J., Arami, H., Saritas, E. U., Croft, L. R., Konkle, J., Goodwill, P. W., Halkola, A., Rahmer, J., et al. (2015) · IEEE Transactions on Medical Imaging · doi:10.1109/tmi.2014.2375065 · Cited by 222
Monodisperse magnetite nanoparticle tracers for in vivo magnetic particle imaging
Khandhar, A. P., Ferguson, R. M., Arami, H., & Krishnan, K. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.087 · Cited by 152
“In fact, Feraheme (ferumoxytol), a dextran-coated iron oxide nanoparticle formulation was approved in 2009 for treatment of iron deficiency anemia in CKD patients [14].”
BackgroundChronic inflammation in multiple sclerosis - seeing what was always there
Matthews, P. M. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0240-y · Cited by 128
Clinical applications of iron oxide nanoparticles for magnetic resonance imaging of brain tumors
Iv, M., Telischak, N., Feng, D., Holdsworth, S. J., Yeom, K. W., & Daldrup-Link, H. E. (2015) · Nanomedicine · doi:10.2217/nnm.14.203 · Cited by 134
Intravenous iron therapy: how far have we come?
Cançado, R. D., & Muñoz, M. (2011) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20110123 · Cited by 94
Design of superparamagnetic nanoparticles for magnetic particle imaging (MPI)
Du, Y., Lai, P., Leung, C., & Pong, P. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140918682 · Cited by 81
“As a result, SPIO nanoparticles are well tolerated in CKD patients and have been used to treat anemia in CKD patients [50].”
BackgroundTracking stem cells with superparamagnetic iron oxide nanoparticles: perspectives and considerations
Jasmin, Souza, G. T., Andrade Louzada, R., Rosado-de-Castro, P. H., Mendez-Otero, R., & Carvalho, A. C. C. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s126530 · Cited by 78
Prediction of anti-cancer nanotherapy efficacy by imaging
Miller, M. A., Arlauckas, S., & Weissleder, R. (2017) · Nanotheranostics · doi:10.7150/ntno.20564 · Cited by 74
MR Angiography of Renal Transplant Vasculature with Ferumoxytol:
Corwin, M. T., Fananapazir, G., & Chaudhari, A. J. (2016) · Academic Radiology · doi:10.1016/j.acra.2015.10.021 · Cited by 35
“It should be noted that cases of severe hypotension and anaphylaxis have been reported after administration of ferumoxytol for therapeutic indications (13,14).”
BackgroundNeiser, S., Koskenkorva, T., Schwarz, K., Wilhelm, M., & Burckhardt, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071185 · Cited by 21
Askri, D., Ouni, S., Galai, S., Chovelon, B., Arnaud, J., Lehmann, S. G., Sakly, M., Sève, M., & Amara, S. (2018) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2018.06.006 · Cited by 11
Metadata
- Authors
- Lu, M., Cohen, M. H., Rieves, D., & Pazdur, R.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2010-04-21
- Volume
- 85
- Issue
- 5
- Pages
- 315-319
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1974023961
- Cited by
- 443
- References
- 27
- FWCI
- 13.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.